These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24429254)

  • 1. TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.
    Simmons JK; Patel J; Michalowski A; Zhang S; Wei BR; Sullivan P; Gamache B; Felsenstein K; Kuehl WM; Simpson RM; Zingone A; Landgren O; Mock BA
    Mol Oncol; 2014 Mar; 8(2):261-72. PubMed ID: 24429254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
    Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
    Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.
    Wang B; Lyu H; Pei S; Song D; Ni J; Liu B
    Cell Cycle; 2018; 17(8):985-996. PubMed ID: 29969371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response.
    Cai B; Lyu H; Huang J; Wang S; Lee CK; Gao C; Liu B
    Cancer Lett; 2013 Jul; 335(2):343-50. PubMed ID: 23459296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
    Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A
    Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining the role of TORC1/2 in multiple myeloma.
    Maiso P; Liu Y; Morgan B; Azab AK; Ren P; Martin MB; Zhang Y; Liu Y; Sacco A; Ngo H; Azab F; Quang P; Rodig SJ; Lin CP; Roccaro AM; Rommel C; Ghobrial IM
    Blood; 2011 Dec; 118(26):6860-70. PubMed ID: 22045983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
    Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
    Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.
    Ramakrishnan VG; Miller KC; Macon EP; Kimlinger TK; Haug J; Kumar S; Gonsalves WI; Rajkumar SV; Kumar SK
    Haematologica; 2019 Oct; 104(10):2061-2074. PubMed ID: 30846494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells.
    Shi Y; Daniels-Wells TR; Frost P; Lee J; Finn RS; Bardeleben C; Penichet ML; Jung ME; Gera J; Lichtenstein A
    Cancer Res; 2016 Oct; 76(19):5822-5831. PubMed ID: 27530328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.
    Dong LH; Cheng S; Zheng Z; Wang L; Shen Y; Shen ZX; Chen SJ; Zhao WL
    J Hematol Oncol; 2013 Jul; 6():53. PubMed ID: 23866964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
    Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
    Oncotarget; 2015 Apr; 6(11):8974-87. PubMed ID: 25797247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
    Hicks KC; Knudson KM; Lee KL; Hamilton DH; Hodge JW; Figg WD; Ordentlich P; Jones FR; Rabizadeh S; Soon-Shiong P; Schlom J; Gameiro SR
    Clin Cancer Res; 2020 Feb; 26(3):704-716. PubMed ID: 31645354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells.
    Beagle BR; Nguyen DM; Mallya S; Tang SS; Lu M; Zeng Z; Konopleva M; Vo TT; Fruman DA
    Oncotarget; 2015 Feb; 6(4):2088-100. PubMed ID: 25576920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators.
    Beider K; Bitner H; Voevoda-Dimenshtein V; Rosenberg E; Sirovsky Y; Magen H; Canaani J; Ostrovsky O; Shilo N; Shimoni A; Abraham M; Weiss L; Milyavsky M; Peled A; Nagler A
    Biochem Pharmacol; 2019 Oct; 168():412-428. PubMed ID: 31325448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
    Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
    Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein.
    Preuss E; Hugle M; Reimann R; Schlecht M; Fulda S
    J Biol Chem; 2013 Dec; 288(49):35287-96. PubMed ID: 24133218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined inhibition of sonic Hedgehog signaling and histone deacetylase is an effective treatment for liver cancer.
    Li J; Cai H; Li H; Liu Y; Wang Y; Shi Y; Sun Y; Song H; Wang D
    Oncol Rep; 2019 Mar; 41(3):1991-1997. PubMed ID: 30747231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors.
    Faes S; Duval AP; Planche A; Uldry E; Santoro T; Pythoud C; Stehle JC; Horlbeck J; Letovanec I; Riggi N; Demartines N; Dormond O
    Mol Cancer; 2016 Dec; 15(1):78. PubMed ID: 27919264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of mTOR signalling potentiates the effects of trichostatin A in human gastric cancer cell lines by promoting histone acetylation.
    Sun DF; Zhang YJ; Tian XQ; Chen YX; Fang JY
    Cell Biol Int; 2014 Jan; 38(1):50-63. PubMed ID: 24030871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells.
    Zeuner S; Vollmer J; Sigaud R; Oppermann S; Peterziel H; ElHarouni D; Oehme I; Witt O; Milde T; Ecker J
    J Neurooncol; 2024 Jan; 166(1):99-112. PubMed ID: 38184819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.